scholarly journals Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future Possibilities

2017 ◽  
Vol 2017 ◽  
pp. 1-14 ◽  
Author(s):  
M. P. M. Graham-Brown ◽  
A. S. Patel ◽  
D. J. Stensel ◽  
D. S. March ◽  
A.-M. Marsh ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Renal Disease ◽  
Myocardial Fibrosis ◽  
End Stage Renal Disease ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Imaging Biomarker ◽  
Imaging Biomarkers ◽  
Stage Renal Disease ◽  
End Stage

Cardiovascular disease in patients with end-stage renal disease (ESRD) is driven by a different set of processes than in the general population. These processes lead to pathological changes in cardiac structure and function that include the development of left ventricular hypertrophy and left ventricular dilatation and the development of myocardial fibrosis. Reduction in left ventricular hypertrophy has been the established goal of many interventional trials in patients with chronic kidney disease, but a recent systematic review has questioned whether reduction of left ventricular hypertrophy improves cardiovascular mortality as previously thought. The development of novel imaging biomarkers that link to cardiovascular outcomes and that are specific to the disease processes in ESRD is therefore required. Postmortem studies of patients with ESRD on hemodialysis have shown that the extent of myocardial fibrosis is strongly linked to cardiovascular death and accurate imaging of myocardial fibrosis would be an attractive target as an imaging biomarker. In this article we will discuss the current imaging methods available to measure myocardial fibrosis in patients with ESRD, the reliability of the techniques, specific challenges and important limitations in patients with ESRD, and how to further develop the techniques we have so they are sufficiently robust for use in future clinical trials.

Left Ventricular Hypertrophy in End-Stage Renal Disease

Nephron ◽  
1988 ◽  
Vol 48 (2) ◽  
pp. 107-115 ◽  
Author(s):  
J.D. Harnett ◽  
P.S. Parfrey ◽  
S.M. Griffiths ◽  
M.H. Gault ◽  
P. Barre ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Stage Renal Disease ◽  
End Stage

Correlative factors of left ventricular hypertrophy in end-stage renal disease

1993 ◽  
Vol 13 (4) ◽  
pp. 252-256 ◽  
Author(s):  
Dai Yong ◽  
He Shi-jiao ◽  
Yu Ying ◽  
Zhu Lan-ying ◽  
Peng Bao ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Intradialytic Arrhythmias Among Patients with End Stage Renal Disease on Maintenance Hemodialysis at Muhimbili National Hospital

2021 ◽  
Author(s):  
Wailesy Adam ◽  
Tumaini Nagu ◽  
Reuben Mutagaywa ◽  
Onesmo Kisanga
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Ventricular Hypertrophy ◽  
Beta Blockers ◽  
Left Ventricular ◽  
Clinically Significant ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Abstract BackgroundArrhythmias are responsible for almost 2 out of 3 cardiac deaths among patients on hemodialysis. We report the prevalence and risk factors for clinically significant arrhythmias among end stage renal disease (ESRD) patients on maintenance dialysis at a tertiary dialysis facility in Tanzania. MethodsCross-sectional study, involving consenting adults with ESRD was conducted September 2019 to February 2020. Arrhythmias were assessed using standard 5-leads Holter electrocardiography placed 15 minutes before dialysis and connected throughout dialysis. Clinically Significant Arrhythmias (CSA) was defined as ectopic beats in excess of 10 per hour or any of the ventricular tachycardia or Pause lasting for at least 2.5 seconds or paroxysmal supraventricular tachycardia or atrial flutter or atrial fibrillation. ResultsA total of 71 (44.4%) participants had CSA. Factors associated with increased risk for CSA were: age older than 60 years (OR 34; 95% CI: 5.15-236; P< 0.001), intradialytic blood pressure change of ≥ 10mmHg (OR 3.85; 95% CI: 1.27-11.7; P=0.017) and the presence of Left Ventricular Hypertrophy (OR 5.84; 95% CI: 1.85-18.4; P< 0.01). On the contrary, three dialysis sessions per week (OR 0.14; 95% CI: 0.03-0.67; P=0.013) and use of beta-blockers (OR 0.18; 95% CI: 0.05-0.68; P=0.011) were significantly associated with a decreased risk of CSA. ConclusionClinically significant arrhythmias are not uncommon in ESRD patients undergoing maintenance haemodialysis. We recommend increasing vigilance for CSA among older patients (>60 years) as well as those with left ventricular hypertrophy. Beta blockers among hypertensive ESRD patients with ventricular hypertrophy could be helpful.

scholarly journals Low agreement between cardiologists diagnosing left ventricular hypertrophy in children with end-stage renal disease

2013 ◽  
Vol 14 (1) ◽  
Author(s):  
Nikki J Schoenmaker ◽  
Johanna H van der Lee ◽  
Jaap W Groothoff ◽  
Gabrielle G van Iperen ◽  
Ingrid ME Frohn-Mulder ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document